Clinical trial
A Trial of Grazax in Subjects With Hayfever
NCT00421655 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00421655 |
|---|---|
| Title | A Trial of Grazax in Subjects With Hayfever |
| Official title | A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Drug |
| Interventions | Grazax |
| Enrollment | 329 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jan 12, 2007 |
| Last update posted | Jun 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: